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Quality of life (QOL) was studied in gastric cancer patients treated on a randomised, controlled trial comparing D1 (level 1) with D3
(levels 1, 2 and 3) lymphadenectomy. A total of 221 patients were randomly assigned to D1 (n¼110) and D3 (n¼111) surgery.
Quality-of-life assessments included functional outcomes (a 14-item survey about treatment-specific symptoms) and health
perception (Spitzer QOL Index) was performed before and after surgery at disease-free status. Patients suffered from irrelative
events such as loss of partners was excluded thereafter. Main analyses were done by intention-to-treat. Thus, 214 D1 (106/
110¼96.4%) and D3 (108/111¼97.3%) R0 patients were assessed. Longitudinal analysis showed that functional outcomes
decreased at 6 months after surgery and increased over time thereafter, while health perceptions increased over time in general. On
the basis of linear mixed model analyses, patients having total gastrectomy, advanced cancer and hemipancreaticosplenectomy, but
not complications had poorer QOL than those without. D1 and D3 patients showed no significant difference in QOL. The results
suggest that changes of QOL were largely due to scope of gastric resection, disease status and distal pancreaticosplenectomy, rather
than the extent of lymph node dissection. This indicates that nodal dissection can be performed for a potentially curable gastric
cancer.
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Gastric cancer remains the second most common cause of cancer-
related deaths worldwide, and a major clinical challenge because of
its poor prognosis and limited treatment options. The efficacy of
nodal dissection is controversial (Cuschieri et al, 1999; Hartgrink
et al, 2004). However, we have conducted a single institutional trial
and demonstrated that D3 surgery has survival benefit (Wu et al,
2006b) but acceptable morbidity (Wu et al, 2004).
Quality of life (QOL) is looked upon as a multidimensional
entity comprising physical, psychological, social and medical
parameters. Cross-sectional studies (Koster et al, 1987; Kusche
et al, 1987; Buhl et al, 1990; Korenaga et al, 1992; Jentschura et al,
1997; Wu et al, 1997a; Zieren et al, 1998; Svedlund et al, 1999;
Thybush-Bernhardt et al, 1999) of QOL after gastric cancer surgery
provided important background for design of this study, delineat-
ing a number of specific hypotheses and research questions related
to surgery and survivorship. This report examines QOL of gastric
cancer patients receiving either D1 or D3 surgery.
MATERIALS AND METHODS
Gastric cancer surgical trial summary
From October 1993 to August 1999, 221 patients were randomised
at laparotomy to compare D1 (level 1) and D3 (level 1, 2 and 3)
lymphadenectomy surgery for gastric cancer (Wu et al, 2004,
2006b). The primary surgical treatment report contains the full
details. D3 surgery had more complications than D1 surgery, but
both had no deaths (Wu et al, 2004, 2006a). No patients received
preoperative or postoperative adjuvant radiotherapy or chemo-
therapy. D3 surgery offers a survival benefit when done by well-
trained, experienced surgeons (Wu et al, 2006b).
Eligibility for the QOL study
The QOL study, a companion protocol, was opened simultaneously
with surgical trial. Patients were eligible if they were registered to
the National Health Research Institutes and had fitted the
requirement of operation criteria and randomisation. The exclusion
criteria included patients not curatively resected and not
treated according to protocol. All patients were at disease-free
status when the survey was carried out, because tumour recurrence
was the decisive exclusion factor. The Ethics Committee approved
the study protocol and an informed consent was obtained from
each patient.
Instruments, assessment strategy and procedures
The Spitzer QOL Index (Spitzer et al, 1981), a global health
assessment with valid questionnaire, includes five items rated on a
three-point scale: activity, daily living, health, support of family
and friends, and outlook. Functional outcome was assessed using a
14-item survey designed to assess treatment-specific symptoms,
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slargely gastrointestinal function. Low scores reflect more symp-
toms (Korenaga et al, 1992; Wu et al, 1997a). Its validity was
checked by the Cronbach’s a-scores.
The assessment strategy focused on QOL at a disease-free status
not to be confounded by irrelevant events such as loss of partners
and bony fractures after falling. We hypothesised that patients
receiving D3 resection would have more symptoms and greater
fatigue than patients receiving D1 surgery, with treatment arm
differences most prominent at the 6-month assessment, and
possibly continuing up to 1 year after random assignment.
Questionnaires were administered at registration, 6 months, 1
year and annually thereafter until recurrence of tumour, if any. A
research nurse (Hsueh-Pin Yu) briefly described and explained the
procedure for responding to each question. Each interview took
approximately 20min.
Statistical considerations and analytic plan
All analyses used the intention-to-treat philosophy, whereby
patients were grouped according to randomly assigned surgery
treatment arms and under the assumption of a missing-at-random
mechanism. The lymph node dissection effects on the functional
outcome, and Spitzer QOL Index were examined by the linear
mixed models (Diggle et al, 2002), adjusting for fixed effects for
each time point, treatment, baseline covariate, age, sex, marital
status, scope of gastric resection and gross appearance of tumour,
and with random effects for intercept and each time point.
Quadratic times as well as interaction terms were considered in the
models to adjust for nonlinear temporal trend. A general
unstructured covariance was assumed, that is, no specific forms
of the random-effects covariance matrix were assumed. The lymph
node dissection effects were assessed based on P-values of the
fitted coefficients, adjusting for significant covariates in the model.
The time trends of the functional outcome and Spitzer Index were
assessed by significance tests of adjacent time periods in the mixed
models, assisted by the longitudinal plots classified by the D1 and
D3 treatment groups. These models and analyses were implemen-
ted by SAS PROC Mixed procedure.
RESULTS
Patient characteristics
In all, 214 R0 patients (mean age 63.9±11.1 years) were recruited.
Comparison of the QOL study sample with the final surgical trial
sample demonstrated no statistical difference between D1 (106/
110¼96.4%) and D3 (108/111¼97.3%) patients in the QOL study
(P¼0.772, w
2 test). Male patients were older (65.43±10.3 vs
58.8±12.2) and underwent more distal pancreaticosplenectomy
procedures. Female patients as compared with male patients were
more likely to be married (100 vs 90.8%). The two groups did not
differ significantly according to age, gender, marital status, type of
gastric resection, reconstructive procedures (Table 1), comorbidity
and location of tumour. But D3 patients had more cholecystect-
omy, distal hemipancreaticosplenectomy procedures (Table 1) and
complications. During follow-up, five patients encountered irrele-
vant events; two spouse suicides (fifth year), three bony fractures
(at second, second and sixth years, respectively). Four patients
immigrated to Mainland China (at second, second, third and third
years, respectively) and therefore could not be assessed at regular
time points thereafter. Quality of life was not assessed at scheduled
across assessment points after surgery in 3.2% of the subjects due
to prolonged absence overseas. The Cronbach’s a-scores for
treatment-specific symptoms were 0.67.
Longitudinal analysis of QOL
Nodal dissection effect showed transient discrepancy of food
volume at baseline, diarrhoea and heartburn at first and second
years after surgery (Table 2). The linear mixed model analysis for
functional outcome showed that there were no significant
differences in scores between two surgical treatment groups
(P¼0.5338, 0.6423 and 0.3941 for nodal dissection effect and its
interaction effects with time and time
2, respectively), after
adjusting for significant covariate effects (Table 3). These
significant covariate effects included time trend, baseline score,
age, gender, gross appearance of tumour, scope of gastric resection
and hemipancreaticosplenectomy. Surgical complications, depth of
cancer invasion and marital status did not affect functional
outcomes, and therefore were dropped from the model. These
results coincide with univariate analyses (which were not shown
here) based on linear mixed effects models when a single covariate
effect is considered, adjusted for time trends and baseline scores.
The overall time trends (Figure 1) indicated that the functional
outcomes were significantly lower at the 6th month after surgical
treatment than at the baseline (Po0.0001), and improved from the
sixth month to the first year after surgery (Po0.0001), con-
tinuously improving up to the second year after surgery
(P¼0.006). Thereafter, the differences in functional outcomes
between adjacent years were not statistically significant. The time
trends of functional outcomes had to be adjusted by significant
interaction effects with time, including scope of gastric resection,
gross appearance of tumour, age and baseline score.
For the Sptizer Index scores, the linear mixed model analysis
revealed similar results that there were no significant differences in
scores between two surgical treatment groups (P¼0.5652, 0.2956
and 0.0784 for node dissection effect and its interaction effects
with time and time
2, respectively), after adjusting for significant
covariate effects (Table 3). The significant covariate effects are
similar to those on the functional outcomes. An interesting finding
is that the marital status is a significant effect on the Sptizer Index
scores, but not on the functional outcomes. The overall health
perceptions (Spitzer Index) (Figure 1) were significantly lower at
the baseline than at the 6th month after surgical treatment
(Po0.0001), and improved from the 6th month to the first year
after surgery (P¼0.0022). Thereafter, there were no significant
Table 1 Patient and operation characteristics
D1 (n¼106) D3 (n¼108) P
Age (years)
Mean (95%) 62.8 (60.6–64.9) 65.0 (62.9–67.0) 0.149
Sex
Men 80 83
Women 26 25 0.813
Marital status
Yes 100 99
No 6 9 0.444
Type of gastric resection
Total gastrectomy 29 22
Distal subtotal gastrectomy 77 86 0.230
Combined resection
Cholecystectomy 14 38 o0.001
Distal pancreaticosplenectomy 1 13 0.001
Segmental resection of colon 3 0 0.120
Splenectomy 3 1 0.015
Partial liver resection 2 1 0.620
Oophorectomy (for ovarian cyst) 1 0 0.495
Reconstructive procedures
Billroth I 6 8
Billroth II 71 78
Roux-en-Y 29 22 0.459
Quality of life after gastric cancer surgery
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Table 2 Effect of nodal dissection on quality of life
Time after operation
Baseline Half year First year Second year Third year Fourth year Fifth year
Disease-specific
symptom
D1
(n¼106)
D3
(n¼108) P-value
D1
(n¼97)
D3
(n¼102) P-value
D1
(n¼82)
D3
(n¼86) P-value
D1
(n¼65)
D3
(n¼62) P-value
D1
(n¼53)
D3
(n¼63) P-value
D1
(n¼45)
D3
(n¼57) P-value
D1
(n¼39)
D3
(n¼54) P-value
Treatment-specific symptoms
Appetite 1.03 (0.58) 0.91 (0.59) 0.13 1.15 (0.46) 1.15 (0.55) 0.92 1.35 (0.55) 1.34 (0.52) 0.84 1.45 (0.53) 1.44 (0.53) 0.91 1.49 (0.50) 1.48 (0.50) 0.88 1.64 (0.48) 1.51 (0.50) 0.17 1.49 (0.51) 1.54 (0.50) 0.64
Consistency of food 1.82 (0.41) 1.82 (0.41) 0.95 1.79 (0.41) 1.83 (0.37) 0.48 1.93 (0.26) 1.92 (0.31) 0.85 1.94 (0.24) 1.97 (0.18) 0.44 2.00 (0.00) 2.00 (0.00) — 2.00 (0.00) 1.98 (0.13) 0.38 1.95 (0.22) 2.00 (0.00) 0.09
Volume of food 0.80 (0.42) 0.68 (0.47) 0.04* 0.48 (0.58) 0.40 (0.58) 0.32 0.87 (0.60) 0.80 (0.61) 0.50 0.95 (0.60) 0.94 (0.62) 0.87 1.00 (0.44) 1.02 (0.49) 0.86 1.07 (0.45) 1.09 (0.39) 0.80 1.26 (0.44) 1.26 (0.44) 0.98
Frequency of eating 1.96 (0.19) 1.94 (0.27) 0.58 1.12 (0.53) 1.21 (0.55) 0.28 1.44 (0.55) 1.51 (0.53) 0.38 1.69 (0.50) 1.66 (0.48) 0.72 1.91 (0.30) 1.84 (0.37) 0.31 1.96 (0.21) 1.96 (0.19) 0.81 1.97 (0.16) 1.98 (0.14) 0.82
Eating time 1.96 (0.19) 1.95 (0.21) 0.76 1.99 (0.10) 1.97 (0.17) 0.34 2.00 (0.00) 2.00 (0.00) — 1.98 (0.12) 1.98 (0.13) 0.97 2.00 (0.00) 2.00 (0.00) — 2.00 (0.00) 2.00 (0.00) — 2.00 (0.00) 2.00 (0.00) —
Postprandial
abdominal fullness
1.19 (0.52) 1.17 (0.56) 0.82 1.41 (0.54) 1.34 (0.47) 0.29 1.50 (0.50) 1.48 (0.50) 0.76 1.54 (0.50) 1.52 (0.50) 0.80 1.47 (0.50) 1.56 (0.50) 0.37 1.49 (0.51) 1.35 (0.48) 0.16 1.54 (0.51) 1.46 (0.50) 0.48
Heartburn 1.71 (0.50) 1.62 (0.59) 0.24 1.95 (0.22) 1.97 (0.17) 0.43 1.95 (0.27) 1.94 (0.24) 0.81 1.88 (0.38) 1.98 (0.13) 0.04* 1.92 (0.27) 1.97 (0.18) 0.29 1.98 (0.15) 1.93 (0.26) 0.27 1.95 (0.22) 1.91 (0.29) 0.46
Diarrhoea 1.81 (0.44) 1.73 (0.54) 0.24 1.82 (0.38) 1.72 (0.47) 0.08 1.88 (0.36) 1.69 (0.51) 0.01* 1.80 (0.40) 1.74 (0.44) 0.44 1.81 (0.39) 1.76 (0.50) 0.56 1.84 (0.37) 1.74 (0.44) 0.19 1.79 (0.47) 1.76 (0.47) 0.72
Constipation 1.78 (0.41) 1.71 (0.53) 0.30 1.85 (0.42) 1.82 (0.43) 0.70 1.82 (0.42) 1.85 (0.39) 0.61 1.88 (0.38) 1.77 (0.46) 0.17 1.87 (0.34) 1.71 (0.49) 0.06 1.62 (0.53) 1.72 (0.45) 0.32 1.64 (0.54) 1.69 (0.47) 0.67
Insomnia 1.88 (0.41) 1.90 (0.34) 0.73 1.86 (0.43) 1.89 (0.31) 0.51 1.84 (0.48) 1.81 (0.45) 0.70 1.85 (0.44) 1.92 (0.27) 0.27 1.83 (0.43) 1.84 (0.41) 0.89 1.82 (0.44) 1.91 (0.29) 0.22 1.79 (0.41) 1.87 (0.34) 0.33
Body weight 1.95 (0.74) 1.81 (0.73) 0.14 1.56 (1.00) 1.38 (0.98) 0.21 1.60 (1.04) 1.50 (1.06) 0.55 1.62 (1.00) 1.69 (0.92) 0.65 1.64 (0.90) 1.75 (0.93) 0.54 1.89 (0.91) 1.77 (0.91) 0.52 1.87 (0.98) 1.85 (0.96) 0.92
Swallowing problem 1.96 (0.19) 1.98 (0.14) 0.42 1.97 (0.23) 1.98 (0.14) 0.68 2.00 (0.00) 1.99 (0.11) 0.33 1.98 (0.12) 1.98 (0.13) 0.97 2.00 (0.00) 2.00 (0.00) — 2.00 (0.00) 2.00 (0.00) — 2.00 (0.00) 2.00 (0.00) —
Vomiting 1.81 (0.44) 1.70 (0.57) 0.10 1.97 (0.17) 1.93 (0.26) 0.22 1.96 (0.19) 1.97 (0.18) 0.95 1.98 (0.12) 1.98 (0.13) 0.97 2.00 (0.00) 2.00 (0.00) — 2.00 (0.00) 1.98 (0.13) 0.38 2.00 (0.00) 2.00 (0.00) —
Dizziness 1.69 (0.54) 1.70 (0.52) 0.83 1.54 (0.52) 1.61 (0.49) 0.28 1.72 (0.55) 1.62 (0.49) 0.20 1.78 (0.41) 1.73 (0.45) 0.44 1.72 (0.45) 1.73 (0.45) 0.88 1.84 (0.37) 1.74 (0.44) 0.19 1.85 (0.37) 1.74 (0.44) 0.23
Spitzer Index
Activity 1.93 (0.25) 1.95 (0.21) 0.53 1.97 (0.17) 1.94 (0.24) 0.35 1.99 (0.11) 1.95 (0.21) 0.19 2.00 (0.00) 1.98 (0.13) 0.31 1.98 (0.14) 1.98 (0.13) 0.90 2.00 (0.00) 1.98 (0.13) 0.38 2.00 (0.00) 2.02 (0.14) 0.40
Daily living 1.99 (0.10) 1.99 (0.10) 0.99 2.00 (0.00) 1.98 (0.14) 0.17 2.00 (0.00) 2.00 (0.00) — 1.98 (0.12) 1.98 (0.13) 0.97 1.98 (0.14) 2.00 (0.00) 0.28 2.00 (0.00) 2.00 (0.00) — 2.00 (0.00) 2.00 (0.00) —
Health 1.70 (0.46) 1.68 (0.47) 0.73 1.72 (0.45) 1.68 (0.47) 0.49 1.84 (0.37) 1.79 (0.41) 0.40 1.89 (0.31) 1.85 (0.36) 0.53 1.94 (0.23) 1.86 (0.35) 0.13 1.87 (0.34) 1.88 (0.33) 0.88 1.87 (0.34) 1.87 (0.34) 0.98
Support 1.93 (0.25) 1.93 (0.26) 0.82 1.99 (0.10) 1.95 (0.22) 0.11 1.99 (0.11) 1.95 (0.21) 0.19 2.00 (0.00) 1.95 (0.22) 0.07 1.98 (0.14) 1.98 (0.13) 0.90 1.93 (0.25) 1.96 (0.19) 0.47 1.95 (0.22) 1.96 (0.19) 0.74
Outlook 1.58 (0.50) 1.61 (0.49) 0.60 1.77 (0.42) 1.76 (0.43) 0.89 1.84 (0.37) 1.80 (0.40) 0.51 1.92 (0.27) 1.87 (0.34) 0.34 1.92 (0.27) 1.89 (0.32) 0.52 1.89 (0.32) 1.91 (0.29) 0.70 1.92 (0.27) 1.91 (0.29) 0.79
*Statistically significant.
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sBuhl et al, 1990). Our treatment-specific instrument, which was
modified from Korenaga’s study for Japanese gastric cancer
patients, is a short questionnaire, which has proved to be reliable
in implementation (Wu et al, 1997a, 2000) and in current study
(Cronbach’s a-scores 0.67). Taken all questionnaires together, data
acquisition for 19 items assisted by a research nurse had shown its
validity throughout the entire study.
Patients had anxiety, depression, loss of appetite and body
weight at diagnosed of gastric cancer, but returned to normal
gradually after surgery. Similar to other observations (Jentschura
et al, 1997; Wu et al, 1997a; Davies et al, 1998), patients after a total
gastrectomy tended to suffer poorer tolerance of normal food,
need for more frequent eating and loss of more body weight than
those after a subtotal gastrectomy. And younger patients had
28
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Figure 1 (A) Average total evaluation score for functional outcome (treatment-specific symptoms), adjusted for time trend and baseline score by
treatment arms. Mean scores are presented with s.e. (bars). High scores reflect better quality of life. (B) Average total evaluation score for general health
perception (Spitzer Index) adjusted for time trend and baseline score by treatment arms. Mean scores are presented with s.e. (bars). High scores reflect
better perception of health status.
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sbetter QOL than older (Koster et al, 1987; Wu et al, 1997a). We
noted that gender plays an important role in facing gastric cancer.
Male patients usually have more morbidity after gastric cancer
surgery (Viste et al, 1988). It is noteworthy that female patients
were younger and mostly married, but male patients tended to feel
better and calmer, suffer less insomnia and have a more positive
outlook. This may not be simply explained by different culture
roles attributes for men and women, since Koster et al (1987) also
recorded the same phenomenon in German gastric cancer patients.
Lymph node dissection along the upper border of the pancreas
is essential for radical gastric cancer surgery. Resection of distal
pancreas to facilitate lymph node dissection had a high morbidity
and mortality. (Bonenkamp et al, 1995; Cuschieri et al, 1996; Wu
et al, 2006a) Our data revealed that diarrhoea, except at first year,
was similarly experienced in both groups. This study further
disclosed its worse functional outcome and health perception, but
no negative effect of QOL among D3 patients was drawn as the
number of affected patients (1% in D1 vs 12% in D3 patients) was
small. However, a technique developed by Maruyama et al (1995)
to preserve the pancreas is feasible and safe, and should be
considered in gastric cancer surgery.
Although the morbidity rate was higher in D3 patients than in
D1 patients, our analysis indicates that lymph node dissection did
not adversely influence QOL. The possible explanations are that
the anastomotic leaks were minor in extent and abscess was
detected early. These patients had no fever and did not need
intensive care. They consumed regular diet while treating by a
closed continuous irrigation system for abscess, and leaks were
managed nonoperatively with nutritional support (Wu et al, 2004)
Nevertheless, one should be very cautious in interpreting these
results because the postoperative morbidity rate was very low, as
compared with other reported studies (Bonenkamp et al, 1995;
Cuschieri et al, 1996). Our previous study and current trial showed
that operative morbidity did not influence survival (Wu et al,
1997b, 2006b). The findings we observed are apparently at variance
with those of a previous study (Siewert et al, 1998). A similar
disparity also exists in QOL.
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